167 related articles for article (PubMed ID: 28865089)
1. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.
Weiss J; Kocher J; Mueller C; Rosenzweig S; Theile D
Biopharm Drug Dispos; 2017 Dec; 38(9):517-525. PubMed ID: 28865089
[TBL] [Abstract][Full Text] [Related]
2. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
3. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Weiss J; Haefeli WE
Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
[TBL] [Abstract][Full Text] [Related]
4. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
5. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetic Studies of Enzalutamide.
Gibbons JA; Ouatas T; Krauwinkel W; Ohtsu Y; van der Walt JS; Beddo V; de Vries M; Mordenti J
Clin Pharmacokinet; 2015 Oct; 54(10):1043-55. PubMed ID: 25917876
[TBL] [Abstract][Full Text] [Related]
8. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
Weiss J; Bajraktari-Sylejmani G; Haefeli WE
Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Gibbons JA; de Vries M; Krauwinkel W; Ohtsu Y; Noukens J; van der Walt JS; Mol R; Mordenti J; Ouatas T
Clin Pharmacokinet; 2015 Oct; 54(10):1057-69. PubMed ID: 25929560
[TBL] [Abstract][Full Text] [Related]
10. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
11. Regulation of drug-metabolizing enzymes and efflux transporters by Astragali radix decoction and its main bioactive compounds: Implication for clinical drug-drug interactions.
Zhang G; Ou R; Li F; Wu J; Zheng L; Tong Y; Liu Y; Liu Z; Lu L
J Ethnopharmacol; 2016 Mar; 180():104-13. PubMed ID: 26805467
[TBL] [Abstract][Full Text] [Related]
12. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
Theile D; Haefeli WE; Weiss J
Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
[TBL] [Abstract][Full Text] [Related]
14. Impact of drug transporters on cellular resistance towards saquinavir and darunavir.
König SK; Herzog M; Theile D; Zembruski N; Haefeli WE; Weiss J
J Antimicrob Chemother; 2010 Nov; 65(11):2319-28. PubMed ID: 20817741
[TBL] [Abstract][Full Text] [Related]
15. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
Blank A; Meier K; Urban S; Haefeli WE; Weiss J
Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
[TBL] [Abstract][Full Text] [Related]
17. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
18. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
Weiss J; Becker JP; Haefeli WE
Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide.
Benoist GE; Hendriks RJ; Mulders PF; Gerritsen WR; Somford DM; Schalken JA; van Oort IM; Burger DM; van Erp NP
Clin Pharmacokinet; 2016 Nov; 55(11):1369-1380. PubMed ID: 27106175
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
Huwyler J; Wright MB; Gutmann H; Drewe J
Curr Drug Metab; 2006 Feb; 7(2):119-26. PubMed ID: 16472102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
